Thomas R Hird Selected Research

dapagliflozin

1/2019

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas R Hird Research Topics

Disease

1	HIV Infections (HIV Infection) 11/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019
1	Carotid Artery Diseases 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Heart Failure 01/2019
1	Peripheral Arterial Disease 01/2019
1	Poliomyelitis (Polio) 01/2012

Drug/Important Bio-Agent (IBA)

1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	RivaroxabanIBA 01/2019
1	dapagliflozinIBA 01/2019
1	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2012

Therapy/Procedure

1	Art Therapy 11/2021
1	Therapeutics 01/2019